Thus, the cumulative effect of stabilin-1+ TAMs must be considered in a cancer-specific context, and taking stabilin-1 as an example, we suggest that blocking SR function to reprogram TAMs is far from simple and unambiguous, reflected by the absence of advanced clinical trials in this direction (for details, see the last chapter of this review). The gene discussed is STAB1; the disease is cancer.